Intravitreal Triamcinolone Acetonide for Refractory Diabetic Macular Oedema
| Autor: | Arosha I Fernando, Jyotin C Pandit |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
medicine.medical_specialty Triamcinolone acetonide genetic structures medicine.drug_class Anti-Inflammatory Agents Case Reports Triamcinolone Acetonide Macular Edema chemistry.chemical_compound Refractory Ophthalmology Medicine Humans Macular edema Diabetic Retinopathy business.industry Retinal Diabetic retinopathy General Medicine Middle Aged medicine.disease Acetonide eye diseases chemistry Diabetic macular oedema Corticosteroid sense organs business medicine.drug |
| Zdroj: | Journal of the Royal Society of Medicine. 98:421-422 |
| ISSN: | 1758-1095 0141-0768 |
| Popis: | Diabetic macular oedema is caused by hyperpermeability of the retinal vasculature and results in retinal thickening due to intraretinal fluid accumulation between the inner and outer plexiform layers. The Early Treatment Diabetic Retinopathy Study defined clinically significant macular oedema (CSMO) by the presence of one or more of the following: retinal thickening at or within 500 mm of the centre of the macula; hard exudates at or within 500 m mo f the macular centre, if associated with adjacent retinal thickening; retinal thickening greater than or equal to one disc area, any part of which is within one disc diameter of the centre of the macular centre.1 Focal argon laser photocoagulation is beneficial in non-ischaemic CSMO but less so in diffuse macular oedema.2 A treatment now used for macular oedema in various diseases is intravitreal triamcinolone acetonide. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|